Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage biopharmaceutical company that is redefining the treatment landscape for chronic diseases by developing proprietary oral drug delivery systems. Founded in 2006 by Israeli scientist Dr. Miriam Kidron and entrepreneur Nadav Kidron, the company is headquartered in New York with a robust research and development presence in Jerusalem, Israel. Oramed’s mission is to revolutionize how patients receive life-saving biologics—transforming injectable therapies into oral alternatives that improve quality of life, increase patient adherence, and enhance treatment outcomes.
At the heart of Oramed’s scientific innovation is its Protein Oral Delivery (POD™) technology, a groundbreaking platform designed to protect therapeutic proteins like insulin from degradation in the gastrointestinal tract and allow for their efficient absorption into the bloodstream. This technology has the potential to disrupt traditional approaches to treating chronic conditions such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH), all of which represent multibillion-dollar global markets with large, underserved patient populations.
Oramed’s lead product candidate, ORMD-0801, is an oral insulin capsule developed for the treatment of type 2 diabetes—a condition that affects more than 500 million people worldwide. By offering an alternative to daily insulin injections, ORMD-0801 could transform diabetes care, reduce treatment resistance, and improve patient compliance. The company has also advanced ORMD-0901, an oral GLP-1 analog, aimed at regulating blood glucose and appetite in patients with type 2 diabetes and metabolic disorders. Both candidates leverage the POD™ platform’s ability to deliver peptide-based therapeutics in a patient-friendly, non-invasive format.
Beyond its proprietary pipeline, Oramed has expanded its reach through strategic partnerships and international collaborations. In China, the company formed a joint venture with Hefei Tianhui Incubator of Technologies (HTIT) to commercialize oral insulin in the world’s largest diabetes market. Oramed has also diversified its innovation portfolio through Oravax Medical Inc., a subsidiary focused on developing oral vaccines, including candidates for COVID-19 and other infectious diseases, capitalizing on global interest in scalable and accessible immunization strategies.
Oramed’s science-driven vision is matched by a commitment to addressing unmet clinical needs and improving patient outcomes across the globe. While the company has faced challenges—including the failure of a late-stage trial in ORMD-0801—it continues to analyze results, identify responsive patient subgroups, and refine its clinical strategy with a long-term growth mindset. Supported by a strong intellectual property portfolio, a scalable technology platform, and a pipeline targeting several of the world’s most burdensome chronic conditions, Oramed remains at the forefront of oral biologics innovation.
As the healthcare industry increasingly shifts toward personalized, less invasive treatments, Oramed Pharmaceuticals is well-positioned to emerge as a category leader. By making biologic therapies easier to access and more convenient to use, Oramed is not just developing drugs—it is fundamentally reshaping the future of therapeutic delivery.
Overcoming Setbacks: From Disappointment to Strategic Reassessment
Despite its ambitious vision, Oramed Pharmaceuticals has faced considerable challenges over the past three years. As reported by Simply Wall St in May 2025, the company’s share price has dropped 53% over that period, with a 10% decline occurring in just the last three months. Much of this downturn can be attributed to investor reaction following the company’s Phase 3 trial results for ORMD-0801, which did not meet its primary efficacy endpoints.
In addition, the company’s revenue has declined 54% annually over the past three years, highlighting the pre-revenue, high-burn nature typical of clinical-stage biotech firms. These financial headwinds, compounded by market uncertainty and lack of near-term profitability, have led to investor pessimism and declining shareholder returns.
However, these challenges must be placed in the proper context. Drug development is an inherently high-risk, high-reward endeavor, particularly in the field of novel delivery mechanisms like oral insulin. The history of pharmaceutical innovation is filled with examples of companies that overcame early clinical or commercial hurdles to deliver game-changing therapies. In Oramed’s case, the company is actively analyzing its Phase 3 data and identifying patient subgroups who may benefit most from ORMD-0801. A refined clinical strategy could yield improved results in future trials or regulatory pathways focused on personalized medicine.
CHECK THIS OUT: Gilead Sciences (GILD) is a Top Long-Term Biotech Investment for 2025 and CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®.
Advancing the Pipeline: Expanding Beyond Insulin to Address Global Metabolic Needs
Oramed is far from a one-product company. Its broader pipeline includes ORMD-0901, an oral GLP-1 receptor agonist that mimics the effects of incretin hormones to regulate blood sugar and appetite. GLP-1s are one of the fastest-growing classes of therapeutics in the world today, with blockbuster drugs like Ozempic and Mounjaro dominating the diabetes and obesity markets. By offering an oral alternative to injectable GLP-1 drugs, Oramed could seize a significant slice of this rapidly expanding market.
Additionally, the company is leveraging its POD™ platform to explore treatments for non-alcoholic steatohepatitis (NASH) and obesity—both massive global health challenges with few effective treatments. These programs reflect Oramed’s long-term commitment to innovation and its strategic intent to diversify revenue sources beyond diabetes management.
Another exciting development is Oramed’s subsidiary, Oravax Medical Inc., which is focused on developing oral vaccines. Originally formed in response to the COVID-19 pandemic, Oravax remains positioned to serve broader infectious disease markets, especially in regions with low healthcare infrastructure where oral vaccines could dramatically improve distribution and compliance.
Strategic Partnerships and Global Commercialization Potential
In addition to its R&D initiatives, Oramed is building value through key strategic partnerships. Notably, the company has formed a joint venture with Hefei Tianhui Incubator of Technologies (HTIT) in China to commercialize oral insulin in the world’s largest diabetic population. The collaboration not only validates Oramed’s scientific credibility but also opens the door to a substantial licensing revenue stream if successful.
Oramed further bolstered its financial position through a $101.9 million strategic financing agreement with Scilex Holding Company. This deal provides much-needed runway for continued clinical development while minimizing dilution. The agreement includes secured notes and warrants that provide long-term upside without sacrificing short-term liquidity—a smart move in a capital-intensive sector.
A High-Risk, High-Reward Opportunity in Biotech Innovation
Oramed Pharmaceuticals is a classic case of a biotech company with transformative potential that has hit short-term turbulence. While the company has experienced stock declines and missed clinical targets, its foundational science, platform versatility, and strategic vision remain intact. For risk-tolerant investors, ORMP offers a compelling speculative opportunity in a biotech segment poised for massive disruption.
With a low market cap relative to its technology platform and intellectual property, Oramed is undervalued compared to its potential. If the company succeeds in re-strategizing its clinical development efforts, validating additional indications, or attracting further partnerships, ORMP stock could experience a significant re-rating.
As Wall Street analysts maintain an average price target of $18.62, compared to a current price of approximately $2.23, the upside potential for investors is substantial. Oramed’s ongoing research, product diversification, and global reach make it one of the more intriguing turnaround plays in the biopharma landscape.
Conclusion: Betting on the Future of Oral Biologics
Oramed Pharmaceuticals is on a bold mission to redefine how the world delivers life-saving biologic therapies. By focusing on oral delivery of insulin, GLP-1s, and vaccines, the company addresses multi-billion-dollar global markets and patient populations in need of easier, more effective treatment options. While recent financial results and clinical setbacks have created headwinds, Oramed’s platform science, global partnerships, and diversified pipeline provide a foundation for future growth and long-term investor value.
For biotech investors with a high tolerance for volatility and a belief in disruptive science, Oramed (NASDAQ: ORMP) could offer an extraordinary reward if the company successfully pivots, revalidates its platform, and executes on its next phase of clinical milestones.
READ ALSO: Incyte (INCY) is the Next Big Biotech Winner and Bluebird Bio (BLUE) Posts 108% Revenue Growth in Q1 2025 Amid Acquisition Buzz.
